http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 DURHAM, N.C.-- November 4, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials. http://pharmalicensing.com/redirs/news_rss//public/news/view/498839/0/13/inspire-completes-patient-enrollment-in-three-late-stage-clinical-trials-in-cystic-fibrosis-dry-eye-and-blepharitis http://pharmalicensing.com/redirs/news_rss//public/news/view/498839/0/13/inspire-completes-patient-enrollment-in-three-late-stage-clinical-trials-in-cystic-fibrosis-dry-eye-and-blepharitis LOUISVILLE, Ky., Oct. 23, 2009 -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today... http://pharmalicensing.com/redirs/news_rss//public/news/view/497060/0/13/potentia-pharmaceuticals-enters-into-licensing-and-purchase-option-agreements-with-alcon-october-2009 http://pharmalicensing.com/redirs/news_rss//public/news/view/497060/0/13/potentia-pharmaceuticals-enters-into-licensing-and-purchase-option-agreements-with-alcon-october-2009